1. Home
  2. SNGX vs DSS Comparison

SNGX vs DSS Comparison

Compare SNGX & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • DSS
  • Stock Information
  • Founded
  • SNGX 1987
  • DSS 1984
  • Country
  • SNGX United States
  • DSS United States
  • Employees
  • SNGX N/A
  • DSS N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • DSS Containers/Packaging
  • Sector
  • SNGX Health Care
  • DSS Consumer Discretionary
  • Exchange
  • SNGX Nasdaq
  • DSS Nasdaq
  • Market Cap
  • SNGX 6.5M
  • DSS 8.9M
  • IPO Year
  • SNGX 1987
  • DSS N/A
  • Fundamental
  • Price
  • SNGX $1.20
  • DSS $0.89
  • Analyst Decision
  • SNGX
  • DSS
  • Analyst Count
  • SNGX 0
  • DSS 0
  • Target Price
  • SNGX N/A
  • DSS N/A
  • AVG Volume (30 Days)
  • SNGX 2.6M
  • DSS 187.4K
  • Earning Date
  • SNGX 08-08-2025
  • DSS 08-12-2025
  • Dividend Yield
  • SNGX N/A
  • DSS N/A
  • EPS Growth
  • SNGX N/A
  • DSS N/A
  • EPS
  • SNGX N/A
  • DSS N/A
  • Revenue
  • SNGX $2,342.00
  • DSS $20,180,000.00
  • Revenue This Year
  • SNGX N/A
  • DSS N/A
  • Revenue Next Year
  • SNGX N/A
  • DSS N/A
  • P/E Ratio
  • SNGX N/A
  • DSS N/A
  • Revenue Growth
  • SNGX N/A
  • DSS 12.88
  • 52 Week Low
  • SNGX $1.20
  • DSS $0.72
  • 52 Week High
  • SNGX $14.83
  • DSS $1.67
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 24.46
  • DSS 46.77
  • Support Level
  • SNGX $1.26
  • DSS $0.88
  • Resistance Level
  • SNGX $1.88
  • DSS $0.96
  • Average True Range (ATR)
  • SNGX 0.12
  • DSS 0.07
  • MACD
  • SNGX -0.04
  • DSS -0.00
  • Stochastic Oscillator
  • SNGX 0.00
  • DSS 41.75

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About DSS DSS Inc.

DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.

Share on Social Networks: